$Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia$

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Background: We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida/Mito) regimen as a salvage treatment of relapsed/refractory acute myeloid leukemia (RR-AML). Methods: A...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Zhang, Zhao Yin, Zurong Yao, Dan Xu, Xuejie Jiang, Xiaqi Nie, Dandan Chen, Hongsheng Zhou, Pengcheng Shi, Hui Liu, Qifa Liu, Guopan Yu
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-02-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207251319603
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Isolated central nervous system relapse in blast crisis of chronic myeloid leukemia: a case report
by: Hari Priya Raghvan, et al.
Published: (2025-01-01)

Bone marrow immune cells and drug resistance in acute myeloid leukemia
by: Miao Zhang, et al.
Published: (2025-02-01)

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
by: Zoe King, et al.
Published: (2025-03-01)

Context and timing matters in acute myeloid leukemia: females are the superior hosts
by: Kerstin B. Kaufmann, et al.
Published: (2025-02-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Annotation-free deep learning for predicting gene mutations from whole slide images of acute myeloid leukemia
by: Bo-Han Wei, et al.
Published: (2025-02-01)

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India
by: Sangita A. Vanik, et al.
Published: (2023-07-01)

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

You Might Not Remember Reading This
by: Robert Schaller, et al.
Published: (2023-05-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study
by: Ishan Hirji, et al.
Published: (2014-09-01)

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia
by: Fei Xie, et al.
Published: (2025-02-01)

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01)

Abnormal sagittal patellar tilt during active knee flexion and extension on 4DCT might be associated with patellofemoral pain
by: Yurou Chen, et al.
Published: (2025-02-01)

A novel truncated fusion gene ETV6::AC010198.2 in post-MPN acute myeloid leukemia caused by del(12)(p13p11)
by: Jiao Lu, et al.
Published: (2025-02-01)

Efficacy of rifaximin in the treatment of chronic relapsing diverticulitis
by: S. I. Achkasov, et al.
Published: (2012-04-01)

Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
by: Ehab L. Atallah, et al.
Published: (2022-08-01)

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)
by: Sarah Bertoli, et al.
Published: (2025-02-01)

Transjugular Portosystemic Shunting in Refractory Cirrhotic Ascites
by: Yu. V. Khoronko, et al.
Published: (2021-04-01)

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
by: Ehab L. Atallah, et al.
Published: (2022-08-01)

Immune‐dysregulation harnessing in myeloid neoplasms
by: Mohammad Jafar Sharifi, et al.
Published: (2024-09-01)

Repeated gastroscopies at impendent relapse of bleeding from gastroduodenal ulcers
by: V. A. Stupin, et al.
Published: (2011-12-01)

Utilisation of an in vivo malaria model to provide functional proof for RhopH1/CLAG essentiality and conserved orthology with P. falciparum
by: Mitchell L. Trickey, et al.
Published: (2025-02-01)

Harnessing amino acid pathways to influence myeloid cell function in tumor immunity
by: Jiongli Pan, et al.
Published: (2025-02-01)

An Overview of the Bovine Leukemia Virus
by: Kaitlyn K. Renegar, et al.
Published: (2023-06-01)

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
by: Peng Sun, et al.
Published: (2025-02-01)

Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus
by: Yasufumi Yorichika, et al.
Published: (2025-02-01)

New opinion on the issue of proton pump inhibitor-refractory gastroesophageal reflux disease
by: Yu. V. Yevsyutina, et al.
Published: (2014-11-01)

Relapse of Psychosis Status Post Meningioma Resection
by: Hamza Mohammad-Amin, et al.
Published: (2021-08-01)

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
by: Rossana Di Staso, et al.
Published: (2024-11-01)

Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
by: Rodrigo Fonseca, et al.
Published: (2025-02-01)

Continuously relapsing (for two years) course of diarrheal variant of IBS (<i>Clinical case</i>)
by: Ye. A. Poluektova, et al.
Published: (2013-10-01)

Myeloid Leukosis (J-virus) - An International Broiler Industry Concern
by: Gary D. Butcher, et al.
Published: (2003-10-01)

Myeloid Leukosis (J-virus) - An International Broiler Industry Concern
by: Gary D. Butcher, et al.
Published: (2003-10-01)

IL-6–174 G/C transversion might decrease male infertility risk: A case-control study
by: Tayyebeh Zamani-Badi, et al.
Published: (2025-02-01)

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
by: Caroline A. Coughlin, et al.
Published: (2025-02-01)

The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data
by: Matthew Schwede, et al.
Published: (2025-02-01)

Review of Interventional Therapies for Refractory Pediatric Migraine
by: Jacquelin Peck, et al.
Published: (2023-01-01)